Literature DB >> 28887053

Modeling the impact of novel male contraceptive methods on reductions in unintended pregnancies in Nigeria, South Africa, and the United States.

Emily Dorman1, Brian Perry2, Chelsea B Polis3, Lisa Campo-Engelstein4, Dominick Shattuck5, Aaron Hamlin6, Abigail Aiken7, James Trussell8, David Sokal9.   

Abstract

OBJECTIVE: We modeled the potential impact of novel male contraceptive methods on averting unintended pregnancies in the United States, South Africa, and Nigeria. STUDY
DESIGN: We used an established methodology for calculating the number of couple-years of protection provided by a given contraceptive method mix. We compared a "current scenario" (reflecting current use of existing methods in each country) against "future scenarios," (reflecting whether a male oral pill or a reversible vas occlusion was introduced) in order to estimate the impact on unintended pregnancies averted. Where possible, we based our assumptions on acceptability data from studies on uptake of novel male contraceptive methods.
RESULTS: Assuming that only 10% of interested men would take up a novel male method and that users would comprise both switchers (from existing methods) and brand-new users of contraception, the model estimated that introducing the male pill or reversible vas occlusion would decrease unintended pregnancies by 3.5% to 5.2% in the United States, by 3.2% to 5% in South Africa, and by 30.4% to 38% in Nigeria. Alternative model scenarios are presented assuming uptake as high as 15% and as low as 5% in each location. Model results were sensitive to assumptions regarding novel method uptake and proportion of switchers vs. new users.
CONCLUSION: Even under conservative assumptions, the introduction of a male pill or temporary vas occlusion could meaningfully contribute to averting unintended pregnancies in a variety of contexts, especially in settings where current use of contraception is low. IMPLICATIONS: Novel male contraceptives could play a meaningful role in averting unintended pregnancies in a variety of contexts. The potential impact is especially great in settings where current use of contraception is low and if novel methods can attract new contraceptive users.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CYP; Male contraception; Male pill; Mathematical model; Reversible vas occlusion; Unintended pregnancy

Mesh:

Year:  2017        PMID: 28887053      PMCID: PMC5732079          DOI: 10.1016/j.contraception.2017.08.015

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  24 in total

1.  Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men.

Authors:  M Cristina Meriggiola; S Cerpolini; W J Bremner; M T Mbizvo; K M Vogelsong; G Martorana; G Pelusi
Journal:  Hum Reprod       Date:  2006-05-26       Impact factor: 6.918

2.  National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis.

Authors:  Leontine Alkema; Vladimira Kantorova; Clare Menozzi; Ann Biddlecom
Journal:  Lancet       Date:  2013-03-12       Impact factor: 79.321

3.  Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen.

Authors:  John K Amory; Stephanie T Page; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner
Journal:  Contraception       Date:  2007-01-16       Impact factor: 3.375

4.  Attitudes toward male fertility control: results of a multinational survey on four continents.

Authors:  Klaas Heinemann; Farid Saad; Martin Wiesemes; Steven White; Lothar Heinemann
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

5.  A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

Authors:  Yi-Qun Gu; Xing-Hai Wang; Dwo Xu; Lin Peng; Li-Fa Cheng; Ming-Kong Huang; Zhen-Jia Huang; Gui-Yuan Zhang
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

6.  Time-to-pregnancy and pregnancy outcomes in a South African population.

Authors:  Braimoh Bello; Danuta Kielkowski; Dick Heederik; Kerry Wilson
Journal:  BMC Public Health       Date:  2010-09-21       Impact factor: 3.295

Review 7.  Male contraception.

Authors:  John K Amory
Journal:  Fertil Steril       Date:  2016-09-24       Impact factor: 7.329

8.  Unmet demand for highly effective postpartum contraception in Texas.

Authors:  Joseph E Potter; Kristine Hopkins; Abigail R A Aiken; Celia Hubert; Amanda J Stevenson; Kari White; Daniel Grossman
Journal:  Contraception       Date:  2014-07-03       Impact factor: 3.051

9.  Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009.

Authors:  John Ross; John Stover
Journal:  Glob Health Sci Pract       Date:  2013-07-26

10.  The contraceptive efficacy of intravas injection of Vasalgel™ for adult male rhesus monkeys.

Authors:  Angela Colagross-Schouten; Marie-Josee Lemoy; Rebekah I Keesler; Elaine Lissner; Catherine A VandeVoort
Journal:  Basic Clin Androl       Date:  2017-02-07
View more
  9 in total

1.  Hormonal Male Contraception: Getting to Market.

Authors:  Stephanie T Page; Diana Blithe; Christina Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-03       Impact factor: 6.055

2.  What About Methods for Men? A Qualitative Analysis of Attitudes Toward Male Contraception in Burkina Faso and Uganda.

Authors:  Alice F Cartwright; Anna Lawton; Aurélie Brunie; Rebecca L Callahan
Journal:  Int Perspect Sex Reprod Health       Date:  2020-09-25

Review 3.  Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.

Authors:  Jill E Long; Min S Lee; Diana L Blithe
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 4.  The future of male contraception: a fertile ground.

Authors:  Iyad Khourdaji; Jacqueline Zillioux; Kevin Eisenfrats; Daniel Foley; Ryan Smith
Journal:  Transl Androl Urol       Date:  2018-05

5.  Catalyzing momentum in male contraceptive development†.

Authors:  Logan M Nickels; Kevin Shane; Heather L Vahdat
Journal:  Biol Reprod       Date:  2022-01-13       Impact factor: 4.285

6.  Acceptability of oral dimethandrolone undecanoate in a 28-day placebo-controlled trial of a hormonal male contraceptive prototype.

Authors:  Brian T Nguyen; Maritza T Farrant; Bradley D Anawalt; Fiona Yuen; Arthi Thirumalai; John K Amory; Ronald S Swerdloff; William J Bremner; Peter Y Liu; Diana L Blithe; Stephanie T Page; Christina Wang
Journal:  Contraception       Date:  2020-04-13       Impact factor: 3.375

7.  Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial.

Authors:  Brian T Nguyen; Fiona Yuen; Maritza Farrant; Arthi Thirumalai; Frances Fernando; John K Amory; Ronald S Swerdloff; Bradley D Anawalt; Diana L Blithe; Jill E Long; Peter Y Liu; Stephanie T Page; Christina Wang
Journal:  Contraception       Date:  2021-06-18       Impact factor: 3.051

8.  Contraceptive Technologies: Looking Ahead to New Approaches to Increase Options for Family Planning.

Authors:  Lisa B Haddad; John W Townsend; Regine Sitruk-Ware
Journal:  Clin Obstet Gynecol       Date:  2021-09-01       Impact factor: 1.966

Review 9.  Male Contraception.

Authors:  Carmen R Abbe; Stephanie T Page; Arthi Thirumalai
Journal:  Yale J Biol Med       Date:  2020-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.